Cognition
Cognition
A major driver of disability and poor outcome, includes attention, decision-making, learning memory, and neuroplasticity.
A major driver of disability and poor outcome, includes attention, decision-making, learning memory, and neuroplasticity.
A major driver of disability and poor outcome, includes attention, decision-making, learning memory, and neuroplasticity.
Emotion and its Regulation
Emotion and its Regulation
Often a difficult-to-treat feature, includes excessive negative (anxiety) or diminished positive emotion (anhedonia).
Often a difficult-to-treat feature, includes excessive negative (anxiety) or diminished positive emotion (anhedonia).
Often a difficult-to-treat feature, includes excessive negative (anxiety) or diminished positive emotion (anhedonia).
Sleep and Activity
Rarely directly assessed or quantified, includes alterations in either sleep or circadian rhythms.
Sleep and Activity
Rarely directly assessed or quantified, includes alterations in either sleep or circadian rhythms.
Rarely directly assessed or quantified, includes alterations in either sleep or circadian rhythms.
PRODUCT CANDIDATE
(TARGET)
(TARGET)
DISCOVERY
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
DISCOVERY
PRE-CLINICAL
PHASE 1
PHASE 2
PHASE 3
ALTO-100
(BDNF)
MDD, PTSD
ALTO-100
(BDNF)
Depression, PTSD
ALTO-100
(BDNF)
MDD, PTSD
ALTO-203
(H3)
MDD
ALTO-300
(MT1/2 & 5-HT2C)
MDD
ALTO-203
(H3)
MDD
ALTO-300
(MT1/2 & 5-HT2C)
MDD
ALTO-202
(NMDA NR2B)
MDD
ALTO-202
(NMDA NR2B)
MDD
ALTO-101
(PDE4)
Schizophrenia
ALTO-101
(PDE4)
Schizophrenia
100'S SERIES NOVEL COMBINATIONS
100 SERIES
(C-AMP PATHWAY)
Neuropsychiatric
100 SERIES - 3 NOVEL COMBINATIONS
100 SERIES
(C-AMP PATHWAY)
Neuropsychiatric
200'S SERIES NOVEL COMBINATIONS
200 SERIES
(DOPAMINE PATHWAY)
Neuropsychiatric, Neurodegenerative
200 SERIES - 3 NOVEL COMBINATIONS
200 SERIES
(DOPAMINE PATHWAY)
Neuropsychiatric, Neurodegenerative
